Tags

Type your tag names separated by a space and hit enter

Reduced mortality with right-lobe living donor compared to deceased-donor liver transplantation when analyzed from the time of listing.
Am J Transplant. 2007 Apr; 7(4):998-1002.AJ

Abstract

Right lobe living donor liver transplantation (RLDLT) is not yet a fully accepted therapy for patients with end-stage liver failure in the Western hemisphere because of concerns about donor safety and inferior recipient outcomes. An outcome analysis from the time of listing for all adult patients who were listed for liver transplantation (LT) at our center was performed. From 2000 to 2006, 1091 patients were listed for LT. One hundred fifty-four patients (LRD; 14%) had suitable live donors and 153 (99%) underwent RLDLT. Of the remaining patients (DD/Waiting List; n = 937), 350 underwent deceased donor liver transplant (DDLT); 312 died or dropped off the waiting list; and 275 were still waiting at the time of this analysis. The LRD group had shorter mean waiting times (6.0 months vs. 9.8 months; p < 0.001). Although medical model for end-stage liver disease (MELD) scores were similar at the time of listing, MELD scores at LT were significantly higher in the DD/Waiting List group (15.4 vs. 19.5; p = 0.002). Patients in Group 1 had a survival advantage with RLDLT from the time of listing (1-year survival 90% vs. 80%; p < 0.001). To our knowledge, this is the first report to document a survival advantage at time of listing for RLDLT over DDLT.

Authors+Show Affiliations

Multi-Organ Transplant Unit, University Health Network, University of Toronto, Toronto, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17391140

Citation

Shah, S A., et al. "Reduced Mortality With Right-lobe Living Donor Compared to Deceased-donor Liver Transplantation when Analyzed From the Time of Listing." American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol. 7, no. 4, 2007, pp. 998-1002.
Shah SA, Levy GA, Greig PD, et al. Reduced mortality with right-lobe living donor compared to deceased-donor liver transplantation when analyzed from the time of listing. Am J Transplant. 2007;7(4):998-1002.
Shah, S. A., Levy, G. A., Greig, P. D., Smith, R., McGilvray, I. D., Lilly, L. B., Girgrah, N., Cattral, M. S., & Grant, D. R. (2007). Reduced mortality with right-lobe living donor compared to deceased-donor liver transplantation when analyzed from the time of listing. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 7(4), 998-1002.
Shah SA, et al. Reduced Mortality With Right-lobe Living Donor Compared to Deceased-donor Liver Transplantation when Analyzed From the Time of Listing. Am J Transplant. 2007;7(4):998-1002. PubMed PMID: 17391140.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduced mortality with right-lobe living donor compared to deceased-donor liver transplantation when analyzed from the time of listing. AU - Shah,S A, AU - Levy,G A, AU - Greig,P D, AU - Smith,R, AU - McGilvray,I D, AU - Lilly,L B, AU - Girgrah,N, AU - Cattral,M S, AU - Grant,D R, PY - 2007/3/30/pubmed PY - 2007/8/1/medline PY - 2007/3/30/entrez SP - 998 EP - 1002 JF - American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons JO - Am J Transplant VL - 7 IS - 4 N2 - Right lobe living donor liver transplantation (RLDLT) is not yet a fully accepted therapy for patients with end-stage liver failure in the Western hemisphere because of concerns about donor safety and inferior recipient outcomes. An outcome analysis from the time of listing for all adult patients who were listed for liver transplantation (LT) at our center was performed. From 2000 to 2006, 1091 patients were listed for LT. One hundred fifty-four patients (LRD; 14%) had suitable live donors and 153 (99%) underwent RLDLT. Of the remaining patients (DD/Waiting List; n = 937), 350 underwent deceased donor liver transplant (DDLT); 312 died or dropped off the waiting list; and 275 were still waiting at the time of this analysis. The LRD group had shorter mean waiting times (6.0 months vs. 9.8 months; p < 0.001). Although medical model for end-stage liver disease (MELD) scores were similar at the time of listing, MELD scores at LT were significantly higher in the DD/Waiting List group (15.4 vs. 19.5; p = 0.002). Patients in Group 1 had a survival advantage with RLDLT from the time of listing (1-year survival 90% vs. 80%; p < 0.001). To our knowledge, this is the first report to document a survival advantage at time of listing for RLDLT over DDLT. SN - 1600-6135 UR - https://www.unboundmedicine.com/medline/citation/17391140/Reduced_mortality_with_right_lobe_living_donor_compared_to_deceased_donor_liver_transplantation_when_analyzed_from_the_time_of_listing_ L2 - https://doi.org/10.1111/j.1600-6143.2006.01692.x DB - PRIME DP - Unbound Medicine ER -